Delcath is a newly profitable small-cap oncology platform—mispriced after a transient revenue wobble—where REMS-driven execution and mCRC trial optionality determine whether HEPZATO becomes a niche cash cow or a breakout franchise.
Overview
Delcath Systems (DCTH) is transitioning from a speculative biotech profile into a profitable small-cap commercial oncology company following the full U.S. launch of HEPZATO KIT, a liver-directed therapy that effectively dominates its niche in metastatic uveal melanoma (mUM). The thesis rests on (1) commercial scalability via a growing REMS-certified center network (25 active sites as of Q3 2025, aiming for ~40 by end-2026) and a high-value per-patient model (AWP ~$219k/kit; multi-cycle courses), (2) a clear financial inflection with gross margins >85%, positive Adjusted EBITDA ($5.3M in Q3 2025), net income, and positive operating cash flow—supported by ~$88.9M cash and zero debt—and (3) pipeline optionality from leveraging the PHP platform into larger indications, especially metastatic colorectal cancer (Phase 2 started Aug 2025; interim 2027). The near-term overhang is execution volatility highlighted by a Q3 2025 revenue miss driven by seasonality and NDRA rebate effects, plus competitive pressure from systemic therapy (Kimmtrak) and simpler liver-directed options (Y-90). Valuation appears discounted versus profitable medtech peers, and insider buying suggests management views the selloff as overdone.